Manufacturing feasibility assessment
5. Verdict
Quantitative capillary-blood HCG is feasible but needs substantial assay, usability, and global IVD validation; start with a CLIA-waived/CE pilot using 50-100 users.
6. Subsystems
- 6.1 Fingerstick sample collectionHIGH
- 6.2 hCG assay cartridgeHIGH
- 6.3 Optical/electrochemical readerMEDIUM
- 6.4 Result interpretation and UXHIGH
- 6.5 Consumable manufacturingHIGH
- 6.6 IVD quality and traceabilityHIGH
7. Bill of materials
| Item | 100 | 1,000 | 10,000 |
|---|---|---|---|
| 7.1 Whole-blood hCG assay cartridge with separator and antibodies | $8.00-$14.00 | $4.50-$7.50 | $2.80-$4.80 |
| 7.2 Reusable optical/electrochemical reader | $14.00-$22.00 | $7.50-$12.00 | $4.50-$7.50 |
| 7.3 Single-use lancet, capillary collector, and alcohol swab | $1.20-$2.40 | $0.70-$1.30 | $0.40-$0.80 |
| 7.4 Calibration references and in-process controls | $1.50-$3.00 | $0.80-$1.60 | $0.45-$0.90 |
| 7.5 Retail carton, instructions, labels, and tamper seal | $1.00-$1.80 | $0.65-$1.10 | $0.40-$0.75 |
| 7.6 Reader assembly, programming, and functional test | $2.50-$4.50 | $1.40-$2.50 | $0.80-$1.50 |
At 100,000 kits, tooling adds about $3-$8 per kit. A $20 retail price cannot reliably carry the estimated $9-$16 10k BOM plus channel margin; $40-$50 retail, a reusable reader model, or bundled refills is the workable route.
8. Gates to clear
8.1 [DFM]
The product must turn an uncontrolled fingerstick sample into a reproducible quantitative hCG result at very low early-pregnancy concentrations.
Path: Run a feasibility program with a whole-blood lateral-flow or electrochemical IVD cartridge manufacturer: characterize 10-50 µL samples, hemolysis, hematocrit, hook effect, interference, and 18-24 month stability before freezing cartridge geometry.
8.2 [Certification]
A global consumer blood IVD needs clinical evidence and jurisdiction-specific authorization; pregnancy-related result interpretation raises usability and labeling scrutiny.
Path: Build under ISO 13485; pursue EU CE marking under IVDR with notified-body involvement, conduct FDA Pre-Submission to establish OTC 510(k) versus De Novo route, then sequence UK MHRA/UKCA, Health Canada, and TGA registrations using the core clinical dossier.
8.3 [Tooling]
At 10k units, the $9-$16 estimated BOM consumes 45%-80% of a $20 retail price before freight, retailer margin, support, and regulatory recovery.
Path: Launch first at $40-$50 with a reader-plus-two-cartridge starter pack, qualify an established IVD CM for higher-volume cartridge production, and target 100k+ annual consumable volume before pursuing a $20-$30 refill pack.
9. Prototype sequence
- 9.1Define intended use: qualitative pregnancy confirmation versus numeric hCG tracking, specimen type, reportable range, and user claims.Claims determine assay precision, clinical study design, labeling, and the FDA/IVDR regulatory route.
- 9.2Build 50-100 engineering cartridges using commercial anti-hCG reagents and a benchtop optical or electrochemical reader.This establishes signal, low-end sensitivity, sample-volume tolerance, and reader repeatability before custom tooling.
- 9.3Run method-comparison and usability studies on fingerstick and venous whole blood through an experienced clinical-study laboratory.The key risk is agreement with laboratory serum/plasma hCG results when used by untrained consumers.
- 9.4Transfer the selected assay to an ISO 13485 IVD contract manufacturer for pilot lots, accelerated aging, and real-time stability.Pilot manufacturing exposes reagent deposition, sealing, lot variation, and shelf-life issues that bench prototypes hide.
- 9.5Hold regulatory pre-submission reviews, lock labeling and risk controls, then execute the jurisdiction-specific clinical validation plan.Early regulator feedback prevents funding a pivotal study against the wrong intended-use and evidence standard.
Assessment criteria: J. Tanikella · Engine: GPT-5.6 Terra.
